Antianxiety effects of lorazepam in patients with cardiovascular symptomatology.
Lorazepam was administered to 38 patients with moderate to severe anxiety associated with cardiovascular symptomatology. A comparable group of patients on placebo (35) served as controls in this 4-week study. Average dosage was 3 mg/day given as 2 mg in the evening and 1 mg in the morning. The Global response, Hamilton Anxiety Rating Scale scores, and 35-Item Self-Rating Scale scores showed lorazepam to be significantly more effective in relieving anxiety than placebo, both clinically and statistically. Adverse reactions were transient and tolerable, and were reported in only 2 patients on lorazepam.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000209:etiology; D002318:Cardiovascular Diseases / Q000523:psychology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D014151:Anti-Anxiety Agents; D010919:Placebos; D008140:Lorazepam